Systemic pharmacological treatments for chronic plaque psoriasis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 2, 2015, Pages

  Sbidian, Emilie ^a   Le Cleach, Laurence ^a   Trinquart, Ludovic ^b   Do, Giao ^a   Hughes, Carolyn ^c   Naldi, Luigi ^d   Garcia Doval, Ignacio ^e   Ingram, John R ^f   Chosidow, Olivier ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CHRONIC PLAQUE PSORIASIS; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

EID: 85031649121     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011535     Document Type: Article

References (70)

1. Atwan A, Abbott R, Kelly MJ, Pickles T, Bauer A, Taylor C, et al. Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010497]
2. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009;219(3):209-18. [MEDLINE: 19657180]
3. Bigby M. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis. Archives of Dermatology 2004;140(3):347-8. [MEDLINE: 15023778]
4. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. British Journal of Dermatology 2008;159(2):274-85. [MEDLINE: 18547300]
5. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271):1842-7. [MEDLINE: 11410193]
6. Christophers E, Mrowietz U, Henneicke HH, Farber L, Welzel D. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. Journal of the American Academy of Dermatology 1992;26(1):86-90. [MEDLINE: 1732342]
7. da Silva CAP, Von Kossel K, Leszczynski M, Melnik T, Riera R. Methotrexate for psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010498]
8. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44. [MEDLINE: 20213715]
9. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. Journal of Investigative Dermatology 2010;130(5):1213-26. [MEDLINE: 19812592]
10. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. New England Journal of Medicine 1991;324(5):277-84. [MEDLINE: 1986287]
11. Flytstrom I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. British Journal of Dermatology 2008;158(1):116-21. [MEDLINE: 17986302]
12. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dose-dependent fashion. Journal of the American Academy of Dermatology 1988;18(4 Pt 1):655-62. [MEDLINE: 2967310]
13. Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technology Assessment 2009;13(Suppl 3):61-6. [MEDLINE: 19846031]
14. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263-71. [MEDLINE: 17658397]
15. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Annals of the Rheumatic Diseases 2005;64(Suppl 2):ii3-8. [MEDLINE: 15708931]
16. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. New England Journal of Medicine 2003;349(7):658-65. [MEDLINE: 12917302]
17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clinical Immunology & Immunopathology 1996;80(3 Pt 2):S40-5. [MEDLINE: 8811062]
19. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, Leon-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. British Journal of Dermatology 1999;141(2):283-91. [MEDLINE: 10468801]
20. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ Canadian Medical Association Journal 2007;176(8):1091-6. [MEDLINE: 17420491]
21. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Archives of Dermatological Research 2007;299(8):359-66. [MEDLINE: 17680257]
22. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. American Journal of Clinical Dermatology 2005;6(6):383-92. [MEDLINE: 16343026]
23. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. British Journal of Dermatology 1998;139(1):88-95. [MEDLINE: 9764154]
24. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. Journal of the American Academy of Dermatology 2007;57(2):347-54. [PUBMED: 17433490]
25. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology 2002;47(6):821-33. [MEDLINE: 12451365]
26. Le Cleach L, Chassany O, Levy A, Wolkenstein P, Chosidow O. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008;216(1):46-55. [MEDLINE: 18032899]
27. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths C E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Archives of Dermatology 2003;139(6):719-27. [MEDLINE: 12810502]
28. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. British Journal of Dermatology 2010;162(1):137-46. [MEDLINE: 19903183]
29. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. New England Journal of Medicine 2003;349(21):2014-22. [MEDLINE: 14627786]
30. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. New England Journal of Medicine 2012;366(13):1190-9. [MEDLINE: 22455413]
31. Lin VW, Ringold S, Devine EB. Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis: A Bayesian Network Meta-analysis. Archives of Dermatology 2012;148:1403-10. [MEDLINE: 23069736]
32. Loveman E, Turner D, Hartwell D, Cooper K, Clegg A. Infliximab for the treatment of adults with psoriasis. Health Technology Assessment 2009;13(Suppl 1):55-60. [MEDLINE: 19567215]
33. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. Journal of Investigative Dermatology 2008;128(5):1207-11. [MEDLINE: 18200064]
34. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004;23(20):3105-24. [MEDLINE: 15449338]
35. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. Journal of the American Academy of Dermatology 1995;32(1):78-88. [MEDLINE: 7822521]
36. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD005028.pub3]
37. Meffert H, Brautigam M, Farber L, Weidinger G. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Dermato-Venereologica 1997;77(2):137-41. [MEDLINE: 9111826]
38. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. Journal of the American Academy of Dermatology 2008;58(1):106-15. [MEDLINE: 17936411]
39. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, Peters JL, et al. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Medical Research Methodology 2009;9:2. [MEDLINE: 19138428]
40. Mrowietz U, Farber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. Journal of the American Academy of Dermatology 1995;33(3):470-5. [MEDLINE: 7657870]
41. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. Journal of Investigative Dermatology 2005;125(1):61-7. [PUBMED: 15982303]
42. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? facts and controversies. Clinics in Dermatology 2010;28(1):67-72. [MEDLINE: 20082954]
43. Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. Journal of the American Academy of Dermatology 2008;58(1):125-35. [MEDLINE: 17996329]
44. Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Archives of Dermatology 2007;143(9):1113-21. [MEDLINE: 17875871]
45. Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. British Journal of Dermatology 2004;150(4):630-2. [MEDLINE: 15099356]
46. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. New England Journal of Medicine 2012;366(13):1181-9. [MEDLINE: 22455412]
47. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology 2013;133(2):377-85. [MEDLINE: 23014338]
48. Pettit JH. Oral retinoid for psoriasis. A report of a double blind study. Acta Dermato-Venereologica. Supplementum 1979;59(85):133-6. [MEDLINE: 393035]
49. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology 1999;41(3 Pt 1):401-7. [MEDLINE: 10459113]
50. Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Current Medical Research & Opinion 2008;24(5):1237-54. [MEDLINE: 18355421]
51. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. British Journal of Dermatology 2012;166(1):179-88. [MEDLINE: 21910698]
52. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71. [MEDLINE: 20688472]
53. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). British Journal of Dermatology 2008;158(3):558-66. [MEDLINE: 18047523]
54. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210(3):194-9. [MEDLINE: 15785046]
55. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology 2008;159(3):513-26. [MEDLINE: 18627372]
56. Shupack J, Abel E, Bauer E, Brown M, Drake L, Freinkel R, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. Journal of the American Academy of Dermatology 1997;36(3 Pt 1):423-32. [MEDLINE: 9091474]
57. Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28(10):935-45. [MEDLINE: 20831302]
58. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. British Journal of Dermatology 1997;137(6):943-9. [MEDLINE: 9470912]
59. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. Journal of Investigative Dermatology 2010;130(4):933-43. [MEDLINE: 20043014]
60. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. Journal of Rheumatology 2006;33(7):1442-6. [MEDLINE: 16724368]
61. Tan JY, Li S, Yang K, Ma B, Chen W, Zha C, et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis. Journal of Dermatological Treatment 2011;22(6):323-36. [MEDLINE: 20923370]
62. Trinquart L, Chatellier G, Ravaud P. Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Medical Research Methodology 2012;12:150. [MEDLINE: 23016799]
63. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis & Rheumatism 2009;60(7):1884-94. [MEDLINE: 19565495]
64. Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technology Assessment 2009;13(Suppl 2):49-54. [MEDLINE: 19804689]
65. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunology 2007;8(9):950-7. [MEDLINE: 17676044]
66. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technology Assessment 2006;10(46):1-233, i-iv. [MEDLINE: 17083854]
67. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. American Journal of Clinical Dermatology 2003;4(7):441-7. [MEDLINE: 12814334]
68. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-51. [MEDLINE: 17187052]
69. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. Journal of the American Academy of Dermatology 2007;57(2):347-54. [PUBMED: 17433490]
70. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. Journal of Investigative Dermatology 2005;125(1):61-7. [PUBMED: 15982303]